Anti-mesothelin antibodies
This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity such as antibody dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to mesothelin expressing cells as well as eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to cells expressing the monoclonal antibodies, polyclonal antibodies, antibody derivatives, such as human, humanized, and chimeric monoclonal antibodies, antibody fragments, mammalian cells expressing the monoclonal antibodies, derivatives and fragments, and methods of treating cancer using the antibodies, derivatives and fragments.
1. A method of determining the presence of a mesothelin-positive cell in a biological sample, said method comprising:
contacting an antibody that binds mesothelin with a biological sample, wherein said antibody comprises a heavy chain variable domain comprising the amino acid
sequence of SEQ ID NO: 2 absent amino acids 1 to 19 thereof and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 4 absent amino
acids 1 to 19 thereof; a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 6 absent amino acids 1 to 19 thereof and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 8 absent amino
acids 1 to 19 thereof; or a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 10 absent amino acids 1 to 19 thereof and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 12 absent amino acids 1 to 19 thereof,
wherein binding of said antibody to said biological sample indicates the presence of said mesothelin-positive cell.
2. A method of determining the presence of a mesothelin-positive cell in a subject, said method comprising detecting binding of an antibody that binds mesothelin to said mesothelin-positive cell, wherein said antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 2 absent amino acids 1 to 19 thereof and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 4 absent amino acids 1 to 19 thereof; a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 6 absent amino acids 1 to 19 thereof and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 8 absent amino acids 1 to 19 thereof; or a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 10 absent amino acids 1 to 19 thereof and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 12 absent amino acids 1 to 19 thereof.
3. The method of claim 2 wherein said detecting is performed subsequent to administration of said antibody to said subject.
4. The method of claim 2 , said method comprising the step of administering said antibody to said subject.
5. The method of claim 1 or claim 2 wherein, wherein the antibody is labeled with a detectable label.
6. The method of claim 5 wherein said detectable label comprises an enzyme, a radioactive agent, a fluorescent agent, or a chromophoric agent.
7. The method of claim 5 wherein said antibody is labeled with Indium-111.
8. The method of claim 5 wherein said antibody is labeled with 111 In-DOTA.
9. The method of claim 1 or 2 wherein said mesothelin-positive cell is a cancer cell presenting mesothelin on its surface.
10. The method of claim 9 wherein said cancer cell is an ovarian cancer cell, a pancreatic cancer cell, a lung cancer cell, or a mesothelioma cell.
11. The method of claim 1 wherein said biological sample comprises ovarian tissue, pancreatic tissue, lung tissue, or mesothelium.
12. The method of claim 1 or 2 wherein the subject is a human.
13. A pharmaceutical composition comprising an antibody that binds to mesothelin, said antibody comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 2 absent amino acids 1 to 19 thereof and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 4 absent amino acids 1 to 19 thereof, a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 6 absent amino acids 1 to 19 thereof and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 8 absent amino acids 1 to 19 thereof; or a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 10 absent amino acids 1 to 19 thereof and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 12 absent amino acids 1 to 19 thereof, wherein said antibody is labeled with a detectable label.
14. The pharmaceutical composition of claim 13 wherein said detectable label comprises an enzyme, a radioactive agent, a fluorescent agent, or a chromophoric agent.
15. The pharmaceutical composition of claim 13 wherein said label comprises Indium-111.
16. The pharmaceutical composition of claim 13 wherein said label comprises 111 In-DOTA.